Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion

Bruno Ambrosi, D. Bochicchio, C. Fadin, P. Colombo, G. Faglia

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Although somatostatin inhibits a variety of pituitary and non-pituitary hormones, not univocal data on its effects on ACTH release have been reported so far. In this study we investigated the effects of somatostatin or octreotide on ACTH levels of patients with corticotropin hypersecretion: 7 patients with Addison’s disease, 2 patients previously adrenalectomized for Cushing’s disease, 4 patients with Cushing’s disease and 3 patients with ectopic ACTH syndrome. Plasma ACTH and Cortisol levels were determined after somatostatin (500μg over 60 min) infusion or octreotide (100μg sc) injection. In 5 other patients with Cushing’s disease ACTH and Cortisol responses to CRH (1 μ/kg iv) were evaluated in basal conditions and after octreotide acute administration. In no patients with Addison’s disease any inhibitory influence of somatostatin (Δ % = −21, −25) or octreotide (Δ % = −38 ± 12 vs −39 ± 12 after saline) on plasma ACTH was found. Somatostatin did not significantly inhibit plasma ACTH in the two patients previously adrenalectomized for Cushing’s disease and in 3 patients with Cushing’s syndrome; in other 4 patients with Cushing’s syndrome octreotide did not affect plasma ACTH levels. In 5 patients with Cushing’s disease the plasma ACTH and Cortisol responses to CRH were similar both before (ACTH from 9.9 ± 1.7 pmol/L to 19.4 ± 6.1 pmol/L; Cortisol from 496 ± 43.9 nmol/L to 923 ± 355 nmol/L) and after octreotide injection (ACTH from 8.8 ± 2.4 pmol/L to 19.1 ± 8.2 pmol/L; Cortisol from 510 ± 54.6 nmol/L to 735 ± 220 nmol/L). In conclusion, the acute administration of somatostatin or octreotide is not able to modify ACTH levels in patients with corticotropin hypersecretion either due to hypo-cortisolemic state or consequent to ACTH-secret-ing pituitary or ectopic tumors; moreover, octreotide does not affect the pituitary-adrenal responsiveness to CRH in patients with Cushing’s disease.

Original languageEnglish
Pages (from-to)257-261
Number of pages5
JournalJournal of Endocrinological Investigation
Volume13
Issue number3
DOIs
Publication statusPublished - 1990

Fingerprint

Octreotide
Somatostatin
Adrenocorticotropic Hormone
Pituitary ACTH Hypersecretion
Hydrocortisone
Addison Disease
Cushing Syndrome
Ectopic ACTH Syndrome
Injections

Keywords

  • ACTH
  • Addison’s disease
  • Cushing’s syndrome
  • Hypothalamic-pituitary-adrenal system
  • octreotide
  • somatostatin

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion. / Ambrosi, Bruno; Bochicchio, D.; Fadin, C.; Colombo, P.; Faglia, G.

In: Journal of Endocrinological Investigation, Vol. 13, No. 3, 1990, p. 257-261.

Research output: Contribution to journalArticle

@article{b5a1595485b54c5988c612842014fba1,
title = "Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion",
abstract = "Although somatostatin inhibits a variety of pituitary and non-pituitary hormones, not univocal data on its effects on ACTH release have been reported so far. In this study we investigated the effects of somatostatin or octreotide on ACTH levels of patients with corticotropin hypersecretion: 7 patients with Addison’s disease, 2 patients previously adrenalectomized for Cushing’s disease, 4 patients with Cushing’s disease and 3 patients with ectopic ACTH syndrome. Plasma ACTH and Cortisol levels were determined after somatostatin (500μg over 60 min) infusion or octreotide (100μg sc) injection. In 5 other patients with Cushing’s disease ACTH and Cortisol responses to CRH (1 μ/kg iv) were evaluated in basal conditions and after octreotide acute administration. In no patients with Addison’s disease any inhibitory influence of somatostatin (Δ {\%} = −21, −25) or octreotide (Δ {\%} = −38 ± 12 vs −39 ± 12 after saline) on plasma ACTH was found. Somatostatin did not significantly inhibit plasma ACTH in the two patients previously adrenalectomized for Cushing’s disease and in 3 patients with Cushing’s syndrome; in other 4 patients with Cushing’s syndrome octreotide did not affect plasma ACTH levels. In 5 patients with Cushing’s disease the plasma ACTH and Cortisol responses to CRH were similar both before (ACTH from 9.9 ± 1.7 pmol/L to 19.4 ± 6.1 pmol/L; Cortisol from 496 ± 43.9 nmol/L to 923 ± 355 nmol/L) and after octreotide injection (ACTH from 8.8 ± 2.4 pmol/L to 19.1 ± 8.2 pmol/L; Cortisol from 510 ± 54.6 nmol/L to 735 ± 220 nmol/L). In conclusion, the acute administration of somatostatin or octreotide is not able to modify ACTH levels in patients with corticotropin hypersecretion either due to hypo-cortisolemic state or consequent to ACTH-secret-ing pituitary or ectopic tumors; moreover, octreotide does not affect the pituitary-adrenal responsiveness to CRH in patients with Cushing’s disease.",
keywords = "ACTH, Addison’s disease, Cushing’s syndrome, Hypothalamic-pituitary-adrenal system, octreotide, somatostatin",
author = "Bruno Ambrosi and D. Bochicchio and C. Fadin and P. Colombo and G. Faglia",
year = "1990",
doi = "10.1007/BF03349555",
language = "English",
volume = "13",
pages = "257--261",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Springer International Publishing",
number = "3",

}

TY - JOUR

T1 - Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion

AU - Ambrosi, Bruno

AU - Bochicchio, D.

AU - Fadin, C.

AU - Colombo, P.

AU - Faglia, G.

PY - 1990

Y1 - 1990

N2 - Although somatostatin inhibits a variety of pituitary and non-pituitary hormones, not univocal data on its effects on ACTH release have been reported so far. In this study we investigated the effects of somatostatin or octreotide on ACTH levels of patients with corticotropin hypersecretion: 7 patients with Addison’s disease, 2 patients previously adrenalectomized for Cushing’s disease, 4 patients with Cushing’s disease and 3 patients with ectopic ACTH syndrome. Plasma ACTH and Cortisol levels were determined after somatostatin (500μg over 60 min) infusion or octreotide (100μg sc) injection. In 5 other patients with Cushing’s disease ACTH and Cortisol responses to CRH (1 μ/kg iv) were evaluated in basal conditions and after octreotide acute administration. In no patients with Addison’s disease any inhibitory influence of somatostatin (Δ % = −21, −25) or octreotide (Δ % = −38 ± 12 vs −39 ± 12 after saline) on plasma ACTH was found. Somatostatin did not significantly inhibit plasma ACTH in the two patients previously adrenalectomized for Cushing’s disease and in 3 patients with Cushing’s syndrome; in other 4 patients with Cushing’s syndrome octreotide did not affect plasma ACTH levels. In 5 patients with Cushing’s disease the plasma ACTH and Cortisol responses to CRH were similar both before (ACTH from 9.9 ± 1.7 pmol/L to 19.4 ± 6.1 pmol/L; Cortisol from 496 ± 43.9 nmol/L to 923 ± 355 nmol/L) and after octreotide injection (ACTH from 8.8 ± 2.4 pmol/L to 19.1 ± 8.2 pmol/L; Cortisol from 510 ± 54.6 nmol/L to 735 ± 220 nmol/L). In conclusion, the acute administration of somatostatin or octreotide is not able to modify ACTH levels in patients with corticotropin hypersecretion either due to hypo-cortisolemic state or consequent to ACTH-secret-ing pituitary or ectopic tumors; moreover, octreotide does not affect the pituitary-adrenal responsiveness to CRH in patients with Cushing’s disease.

AB - Although somatostatin inhibits a variety of pituitary and non-pituitary hormones, not univocal data on its effects on ACTH release have been reported so far. In this study we investigated the effects of somatostatin or octreotide on ACTH levels of patients with corticotropin hypersecretion: 7 patients with Addison’s disease, 2 patients previously adrenalectomized for Cushing’s disease, 4 patients with Cushing’s disease and 3 patients with ectopic ACTH syndrome. Plasma ACTH and Cortisol levels were determined after somatostatin (500μg over 60 min) infusion or octreotide (100μg sc) injection. In 5 other patients with Cushing’s disease ACTH and Cortisol responses to CRH (1 μ/kg iv) were evaluated in basal conditions and after octreotide acute administration. In no patients with Addison’s disease any inhibitory influence of somatostatin (Δ % = −21, −25) or octreotide (Δ % = −38 ± 12 vs −39 ± 12 after saline) on plasma ACTH was found. Somatostatin did not significantly inhibit plasma ACTH in the two patients previously adrenalectomized for Cushing’s disease and in 3 patients with Cushing’s syndrome; in other 4 patients with Cushing’s syndrome octreotide did not affect plasma ACTH levels. In 5 patients with Cushing’s disease the plasma ACTH and Cortisol responses to CRH were similar both before (ACTH from 9.9 ± 1.7 pmol/L to 19.4 ± 6.1 pmol/L; Cortisol from 496 ± 43.9 nmol/L to 923 ± 355 nmol/L) and after octreotide injection (ACTH from 8.8 ± 2.4 pmol/L to 19.1 ± 8.2 pmol/L; Cortisol from 510 ± 54.6 nmol/L to 735 ± 220 nmol/L). In conclusion, the acute administration of somatostatin or octreotide is not able to modify ACTH levels in patients with corticotropin hypersecretion either due to hypo-cortisolemic state or consequent to ACTH-secret-ing pituitary or ectopic tumors; moreover, octreotide does not affect the pituitary-adrenal responsiveness to CRH in patients with Cushing’s disease.

KW - ACTH

KW - Addison’s disease

KW - Cushing’s syndrome

KW - Hypothalamic-pituitary-adrenal system

KW - octreotide

KW - somatostatin

UR - http://www.scopus.com/inward/record.url?scp=0025277838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025277838&partnerID=8YFLogxK

U2 - 10.1007/BF03349555

DO - 10.1007/BF03349555

M3 - Article

C2 - 1973178

AN - SCOPUS:0025277838

VL - 13

SP - 257

EP - 261

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 3

ER -